Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making

Am J Clin Oncol. 2016 Apr;39(2):214. doi: 10.1097/COC.0000000000000253.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / economics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Camptothecin / analogs & derivatives
  • Camptothecin / economics
  • Camptothecin / therapeutic use
  • Cetuximab / economics*
  • Cetuximab / therapeutic use*
  • Clinical Decision-Making
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / economics*
  • Cost-Benefit Analysis*
  • Fluorouracil / economics
  • Fluorouracil / therapeutic use
  • Leucovorin / economics
  • Leucovorin / therapeutic use
  • Quality-Adjusted Life Years

Substances

  • Antineoplastic Agents
  • Cetuximab
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • IFL protocol